ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Supriya Lifescience Limited conducted its 18th Annual General Meeting on September 24, 2026. All resolutions proposed in the meeting were passed with the requisite majority.
Bombay High Court ordered provisional release of 200 kg Ketamine Hydrochloride consignment subject to ₹0.72 Crore deposit. Criminal and NDPS proceedings continue.
Supriya Lifescience explained missing segment details in its Q2 FY27 quick results filing. The omission was a technical XBRL display error; the company operates in one segment.
The company informs exchanges that it has dispatched communication regarding the Annual Report web link to shareholders with unregistered email IDs.
Supriya Lifescience Limited informed stock exchanges that there have been no new developments regarding ongoing judicial proceedings involving its General Manager.
Supriya Lifescience Ltd has issued the notice for its 18th Annual General Meeting scheduled for September 24, 2026, alongside the Annual Report for FY 2025-26.
Supriya Lifescience Limited has fixed September 4, 2026, as the record date for its final dividend of Re. 1.00 per share. The dividend awaits AGM approval.
Supriya Lifescience Ltd. shareholders approved the re-appointment of Mr. Balasaheb Sawant as Whole Time Director via postal ballot, as per the voting results.
Supriya Lifescience is pivoting to Finished Dosage Forms (FDF) and R&D-driven specialized therapies with a new dedicated manufacturing unit. Focus is on high-margin Anaesthetic, Anti-diabetic, and CNS portfolios.
Supriya Lifescience announced financial highlights for Q1 FY27, reporting revenue of Rs. 189.75 crore and profit after tax of Rs. 24.04 crore for the quarter.
Supriya Lifescience reported Q1 FY27 revenue of INR 1,897.5 Mn, up 31% YoY, despite EBITDA and PAT compression. The company is pivoting towards new markets and backward integration to stabilize margins.
Supriya Lifescience Ltd reported revenue from operations of ₹189.7 Cr (+30.7% YoY) and net profit of ₹24 Cr (-31.0% YoY) for Q1 FY27.
Supriya Lifescience Ltd scheduled a board meeting for August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Supriya Lifescience Ltd issued a Postal Ballot Notice to shareholders seeking approval for the re-appointment of Mr. Balasaheb Sawant as a Whole Time Director.
Supriya Lifescience Ltd has submitted its quarterly shareholding pattern under SEBI regulations. This filing discloses the stake distribution among promoters and the general public.